Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 5/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879868 | 1.00 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14879850 | 0.80 | SMN1; SMN2 (0.37) | POLBSMN1; SMN2KMT2A | |
| SCHEMBL8571586 | 0.73 | TSHR (0.37) | TSHRFDPSGGPS1KMT2AHTT | |
| SCHEMBL9839462 | 0.70 | CYP3A4 (0.33) | POLBSMN1; SMN2 | |
| SCHEMBL15874145 | 0.70 | APLNR (0.39) | POLBSMN1; SMN2TSHR | |
| SCHEMBL14879952 | 0.70 | CYP3A4 (0.35) | — | |
| SCHEMBL18237168 | 0.70 | CYP3A4 (0.35) | — | |
| SCHEMBL1804322 | 0.68 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21380508 | 0.67 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14879887 | 0.67 | UGT2B7 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768307-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9499464-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | CRYAB, CRYAA, PDE6C | CHRNB2 219/4885CHRNA4 789/4885CHRNB4 268/4885 |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, PDE6C, CRYAA | CHRNB2 263/4885CHRNA4 855/4885CHRNB4 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.